share_log

Earnings Call Summary | PDS Biotechnology(PDSB.US) Q4 2023 Earnings Conference

Futu News ·  Mar 28 00:35  · Conference Call

The following is a summary of the PDS Biotechnology Corporation (PDSB) Q4 2023 Earnings Call Transcript:

Financial Performance:

  • PDS Biotechnology Corporation reported a net loss of approximately $42.9 million or $1.39 per basic and diluted share for the year ended December 31, 2023.

  • The operating expenses for the year 2023 were $43 million and the cash balance as of December 31, 2023, was $56.6 million.

Business Progress:

  • There have been key developments in the clinical programs of the company, particularly PDS01ADC and PDS0101 Phase 2 programs.

  • The company made a strategic decision to focus on its triple combination treatment for HNSCC based on positive results from Phase 2 trials.

  • There have been changes in company leadership with new members joining the PDS Biotech Leadership Team.

  • An IND for PDS0103 is planned to be filed in the second half of 2024.

  • Various trials are ongoing in collaboration with the National Cancer Institute, although the primary focus is on the triple combination treatment.

More details: PDS Biotechnology IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment